To the current body of evidence, our study seems to be the first RCT assessing the influence of MI supplementation on IR through AMPK/PI3K/AKT signaling pathway in obese patients with NAFLD. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.